To evaluate the efficacy and safety of ramucirumab ( IMC-1121B ; LY3009806 ) , a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2 , alone and in combination with dacarbazine in chemotherapy-nave patients with metastatic melanoma ( MM ) .